Radiopharmaceutical Dealmaking Continues With Telix’s $1.65B ITM Acquisition
Telix Pharmaceuticals is acquiring Isotope Technologies Munich, or ITM, in a $1.65 billion stock deal that will create a radiopharmaceuticals company with greater global scale. ITM’s lead pipeline asset is in late-stage development for a type of gastrointestinal cancer, where it could compete against Novartis and Curium Pharma products.
Array Behavioral Care Unveils New Triage Model
Array Behavioral Care launched a new service to help providers assess patients with urgent behavioral health needs and connect them to appropriate care.
How AI Is Transforming Clinical Documentation at Intermountain Health
Since implementing AI clinical documentation improvement (CDI) tools, Intermountain has seen a 22% point increase in inpatient chart completion during or immediately after rounds.
The Nurse Is Health Care’s Most Underpriced Founder
They see the problem first, build the fix, and decide whether it is ever adopted. The market has trained them to hide the one credential that de-risks the deal.
Electra’s Upsized IPO Lands $350M for New Class of Precision Immunology Drugs
Electra Therapeutics’ IPO cash will support a potential first-in-class drug whose lead indication is a rare hyperinflammatory disorder with no FDA-approved treatments. Meanwhile, clinical-stage biotechs Marea Therapeutics and Sensorion revealed their respective plans to enter the U.S. public markets.